bibibi.ccLoading…
Connect scattered updates into a story you can understand.
According to Beating AI, Formation Bio has established a 600000000 USD fund and plans over the next 3 to 5 years to acquire or in-license 10 to 15 drug candidate projects, and has already secured licenses for projects.
Citrini and Anthropic tested Claude-generated scorpion antivenom protein designs; in testing, 17 candidates could bind to the target toxin, but they have not been shown to neutralize the venom. Based on this, Citrini is focusing on opportunities in outsourced drug development research, testing equipment, and automation tools.
Iambic Therapeutics issued approximately 16 USD shares at a per-share price of 9380000, in the United States IPO IPO 150000000 USD, and is expected to trade on Nasdaq on October 15 under the ticker IAM.